| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5559111 | NOVARTIS | δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168616 | NOVARTIS | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
Jul, 2026
(2 years from now) | |
Valturna is owned by Novartis.
Valturna contains Aliskiren Hemifumarate; Valsartan.
Valturna has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Valturna are:
- US5559111
Valturna was authorised for market use on 16 September, 2009.
Valturna is available in tablet;oral dosage forms.
Valturna can be used as treatment of hypertension.
Drug patent challenges can be filed against Valturna from 06 March, 2011.
The generics of Valturna are possible to be released after 03 July, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Combination(NC) | Sep 16, 2012 |
Drugs and Companies using ALISKIREN HEMIFUMARATE; VALSARTAN ingredient
NCE-1 date: 06 March, 2011
Market Authorisation Date: 16 September, 2009
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
More Information on Dosage
VALTURNA family patents
